Effect of an oral therapeutic HIV-1 vaccine on aids patients with CD4 count above 250 cells/MM3

Acta Virologica

Volumn 48, Issue 2, 2004, Pages 73-78

  Jirathitikal, V ^a   Bourinbaiar, A S ^b  

^a Bangpakong Industrial Park   (Thailand)

^b Immunitor USA Inc   (United States)

Author keywords

Antiviral therapy; Cellular immunity; Clinical trials; Gut, immune based therapy; Therapeutic vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MUCOSAL IMMUNITY; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; WEIGHT GAIN; APPETITE; BLOOD; BODY WEIGHT; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; THAILAND; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AIDS VACCINES; APPETITE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; THAILAND; VACCINATION; VIRAL LOAD; VIREMIA;

EID: 7944220489     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Asjo B, Stavang H, Sorensen B, Baksaas I, Nyhus J, Langeland N (2002): Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res. Hum. Retrovir. 18, 1357-1365.
2. Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF (1998): Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS 12, 1291-1300.
3. Benson EM, Clarkson J, Law M, Marshall P, Kelleher AD, Smith DE, Patou G, Stewart GJ, Cooper DA, French RA (1999): Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res. Hum. Retrovir. 15, 105-113.
4. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR (2000): Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J. Infect. Dis. 181, 881-889.
5. Bourinbaiar A, Minowada, J (1989): Does adult T-cell leukaemia originate from intestinal mucosa. Lancet 1, 1019.
6. Bourinbaiar AS (1994): Mucosal origin of AIDS. Med. Hypotheses 42, 43-44.
7. Bourinbaiar AS, Lee-Huang S (1995): Rational problems associated with the development of cellular approaches in controlling HIV spread. Adv. Exp. Med. Biol. 374, 71-89.
8. Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB (1999): Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin. Immunol. 90, 100-107.
9. Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, Vacharak P, Grimes J, Theofan G, Carlo DJ (1998): Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS 12, 1521-1527.
10. Churdboonchart V, Sakondhavat C, Kulpradist S, Na Ayudthya BI, Chandeying V, Rugpao S, Boonshuyar C, Sukeepaisarncharoen W, Sirawaraporn W, Carlo DJ, Moss R (2000): A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300. Clin. Diagn. Lab. Immunol. 7, 728-733.
11. Eron JJ Jr, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T (1996): Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 348, 1547-1551.
12. Essajee SM, Yogev R, Pollack H, Greenhouse B, Krasinski K, Borkowsky W (2002): Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies. Clin. Diagn. Lab. Immunol. 9, 79-82.
13. Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle V, Kunschak M, Engl W (2000): Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 13, 1461-1468.
14. Jirathitikal V, Bourinbaiar AS (2002): Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease. HIV Clin. Trials 3, 21-26.
15. Jirathitikal V, Metadilogkul O, Bourinbaiar AS (2003a): Normalization of elevated liver enzymes due to V-1 Immunitor therapy. Electr. J. Biotechnol. 6, 76-79 (online peer-reviewed journal www.ejbiotechnology.info/content/vol6/issue1/full/3/reprint.html).
16. Jirathitikal V, Sooksathan P, Metadilogkul O, Bourinbaiar AS (2003b): V-1 Immunitor: Oral AIDS vaccine with therapeutic and prophylactic potential. Vaccine 21, 624-628.
17. Jirathitikal V, Metadilogkul O, Bourinbaiar AS (2004): Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration. Eur. J. Clin. Nutrition 58, 110-115.
18. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S (2000): Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 106/L CD4 cell counts: A randomized controlled trial. JAMA 284, 2193-2202.
19. Kinloch-de Loes S, Autran B (2002): HIV-1 therapeutic vaccines. J. Infect. 44, 152-159.
20. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC (1998): A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retrovir. 14, 551-560.
21. 3 (AIDS Clinical Trials Group Study 246/946). AIDS Res. Hum. Retrovir. 17, 1371-1378.
22. Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J Jr, Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G (1998): Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). J. Acquir. Immune Defic. Syndr. Hum. Retroviral. 19, 451-461.
23. Lisziewicz J, Bakare N, Lori F (2003): Therapeutic vaccination for future management of HIV/AIDS. Vaccine 21, 620-623.
24. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, Deschenes GR, Ramanathan M Jr, Barsoum S, Vander hoeven J, He T, Chung C, Murray J, Perelson AS, Zhang L, Ho DD (2002): Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J. Infect. Dis. 186, 634-643.
25. Metadilogkul O, Jirathitikal V, Bourinbaiar AS (2002): Survival of end-stage patients receiving V-1 Immunitor. HIV Clin. Trials 3, 258-259.
26. Phanuphak P, Tan-ud P, Panitchpakdi P, Tien-udom N, Nagapiew S, Cawthorne P (2002): V-1 Immunitor. HIV Clin. Trials 3, 260-261.
27. Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R (1999): HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13, 2003-2012.
28. Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, Tamburrini E, Prozzo A, Seeber AC, Vella S, Ortona L, Aiuti F (1998): Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS 12, 473-480.
29. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A (1991): A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N. Engl. J. Med. 321, 1677-1684.
30. Sabin C (2002): V-1 Immunitor: Editorial comments. HIV Clin. Trials 3, 259-260.
31. Sandstrom E, Wahren B (1999): Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 353, 1735-1742.
32. Seth A, Yasutomi Y, Jacoby H, Callery JC, Kaminsky SM, Koff WC, Nixon DF, Letvin NL (2000): Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res. Hum. Retrovir. 16, 337-343.
33. Schedel I, Sutor GC, Hunsmann G, Jurkiewicz E (1999): Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Vaccine 17, 1837-1845.
34. Schwander S, Opravil M, Luthy R, Hanson DG, Schindler J, Dawson A, Letwin B, Dietrich M (1994): Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll. Infection 22, 86-91.
35. Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, Boag F, Hales G, Adams S, Patou G, Cooper DA (2001): Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med. 2, 272-275.
36. Sukeepaisarncharoen W, Churdboonchart V, Kulpradist S, Isarangkura Na Ayudthya B, Rugpao S, Chandeying V, Sirawaraporn W, Carlo D, Moss RB (2001): Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy. HIV Clin. Trials 2, 391-398.
37. Tubiana R, Gomard E, Fleury H, Gougeon ML, Mouthon B, Picolet H, Katlama C (1997): Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 11, 819-820.
38. Turner JL, Kostman JR, Aquino A, Wright D, Szabo S, Bidwell R, Goodgame J, Daigle A, Kelley E, Jensen F, Duffy C, Carlo D, Moss RB (2001): The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med. 2, 68-77.
39. Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, Merigan TC (1996): A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J. Infect. Dis. 173, 1336-1346.
40. Veenstra J, Williams IG, Colebunders R, Dorrell L, Tchamouroff SE, Patou G, Lange JM, Weller IV, Goeman J, Uthayakumar S, Gow IR, Weber JN, Coutinho RA (1996): Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J. Infect. Dis. 174, 862-866.
41. Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J (1999): Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J. Infect. Dis. 180, 1080-1088.
42. Zagury D, Leonard R, Fouchard M, Reveil B, Bernard J, Ittele D, Cattan A, Zirimwabagabo L, Kalumbu M, Justin W (1987): Immunization against AIDS in humans. Nature 326, 249-250.
43. Ziegner UH, Peters G, Jolly DJ, Mento SJ, Galpin J, Prussak CE, Barber JR, Hartnett DE, Bohart C, Klump W (1995): Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins. AIDS 9, 43-50.